Clinical Trial Update: Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients [Phase 2]

View source ↗

Summary

A Phase II trial evaluating clofarabine in pediatric patients with acute myeloid leukemia has completed. The study was sponsored by Genzyme (a Sanofi company).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Clolar (Clofarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Leukemia, Myelocytic, Acute, Pediatric | Phase 2 | Status: COMPLETED